Article Text

Download PDFPDF
How not to test the prevalence of therapeutic misconception
  1. Paul S Appelbaum
  1. Department of Psychiatry, Columbia University, NY State Psychiatric Institute, New York, New York, USA
  1. Correspondence to Dr Paul S Appelbaum, Columbia University, NY State Psychiatric Institute, 1051 Riverside Drive, Unit 122, New York, NY 10032, USA; psa21{at}

Statistics from

Almost 35 years ago, my colleagues and I first reported a new phenomenon: the decisions of many freshly enrolled research subjects appeared to be based on confusion between the nature of research and of ordinary treatment.1 We called the phenomenon ‘therapeutic misconception’ (TM), and noted that it was characterised by inaccurate beliefs about the degree of individualisation of treatment and likelihood of benefit associated with enrolment in a clinical trial. Since that original paper, dozens of studies from around the world have confirmed the existence of TM and its substantial prevalence, with rates of some degree of TM approaching or exceeding 50% in many studies.2 The concept of TM has become a given in the world of research ethics.

Commonly accepted concepts, of course, are prime targets for academic revisionism, so it is not a surprise to see an article like that by Kim et al in this issue of JME.3 Indeed, Kim et al have embarked on a series of studies aimed at challenging the idea that TM is a major concern in consent to research. This is not the place to comment on the project as a whole, but the study reported here exemplifies its problems. It is based on the notion that “the apparent prevalence of TM indicates [sic] a form of measurement error”, that …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles